The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck Serono
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Lin Shen
Honoraria - Bayer; Hengrui Pharmaceutical; Merck; Roche; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Hengrui Pharmaceutical; Roche; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Hengrui Pharmaceutical; Merck; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Hengrui Pharmaceutical; Roche
 
Brigette Ma
Honoraria - Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Merck Serono; Merck Sharp & Dohme; Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Amgen
 
Regina Esser
Employment - Merck KGaA
 
Wen-Feng Chen
No Relationships to Disclose
 
Peter Gibbs
Honoraria - Amgen; Merck; Roche; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Ventana Medical Systems (Inst)
 
Robert S.C. Lim
No Relationships to Disclose
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi